To study the efficacy of the p38 MAPK inhibitor on MMP activity modulation in ischemic stroke, the immunofluorescence staining of MMP-2 and MMP-9 expression was obtained on day 14 post-stroke (Fig. 7A). Here, MMP9 is linked to ischemic stroke.